The American Journal of Medicine
Volume 123, Issue 4 , Pages 350-357 , April 2010

Coronary Heart Disease and Stroke Risk in Patients with Psoriasis: Retrospective Analysis

  • Alexa Boer Kimball, MD, MPH

      Affiliations

    • Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationReprint requests should be addressed to Alexa Boer Kimball, MD, MPH, Vice Chair, Department of Dermatology, Massachusetts General Hospital, Associate Professor, Harvard Medical School, Director, Clinical Unit for Research Trials in Skin (CURTIS), 50 Staniford Street, #246, Boston, MA 02114
    • ,
  • Annie Guerin, MSc

      Affiliations

    • Analysis Group, Boston, Mass
    • ,
  • Dominick Latremouille-Viau, MA

      Affiliations

    • Analysis Group, Boston, Mass
    • ,
  • Andrew P. Yu, PhD

      Affiliations

    • Analysis Group, Boston, Mass
    • ,
  • Shiraz Gupta, PharmD, MPH

      Affiliations

    • Abbott Laboratories, Abbott Park, Ill
    • ,
  • Yanjun Bao, PhD

      Affiliations

    • Abbott Laboratories, Abbott Park, Ill
    • ,
  • Parvez Mulani, PhD

      Affiliations

    • Abbott Laboratories, Abbott Park, Ill

References 

  1. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–835
  2. Schmitt J, Ford DE. Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis—a structural equations modeling approach. Gen Hosp Psychiatry. 2007;29:134–140
  3. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59:772–780
  4. McDonald CJ. Cardiovascular disease in psoriasis. J Invest Dermatol. 1989;92:646–647
  5. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982–986
  6. Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat. 2005;16:319–323
  7. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome (A cross-sectional study). Dermatology. 2008;216:152–155
  8. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6:813–820
  9. Helms C, Saccone NL, Cao L, et al. Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet. 2005;118:466–476
  10. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493–1499
  11. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol. 2007;57:347–354
  12. Wakkee M, Thio HB, Prens EP, et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190:1–9
  13. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19:5–21
  14. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159:895–902
  15. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol. 2008;7:373–377
  16. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606
  17. Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007;18:25–31
  18. Saurat JH, Stingl G, Dubertret L, et al. CHAMPION Study Investigators Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–566
  19. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–115
  20. Haq IU, Ramsay LE, Yeo WW, et al. Is the Framingham risk function valid for northern European populations? (A comparison of methods for estimating absolute coronary risk in high risk men). Heart. 1999;81:40–46
  21. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  22. Linn S, Fulwood R, Carroll M, et al. Serum total cholesterol: HDL cholesterol ratios in US white and black adults by selected demographic and socioeconomic variables (HANES II). Am J Public Health. 1991;81:1038–1043
  23. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication (The Framingham Study). Stroke. 1994;25:40–43
  24. Nair D, Carrigan TP, Curtin RJ, et al. Association of coronary atherosclerosis detected by multislice computed tomography and traditional risk-factor assessment. Am J Cardiol. 2008;102:316–320
  25. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol. 2008;7:563–572
  26. Grundy SM, Greenland P, Herd A, et al. Cardiovascular and risk factor evaluation of healthy American adults (A statement for physicians by an Ad Hoc Committee appointed by the Steering Committee, American Heart Association). Circulation. 1987;75:1340A–1362A
  27. Gartside PS, Wang P, Glueck CJ. Prospective assessment of coronary heart disease risk factors: the NHANES I epidemiologic follow-up study (NHEFS) 16-year follow-up. J Am Coll Nutr. 1998;17:263–269
  28. World Health Organization. BMI classification. http://www.who.int/bmi/index.jsp?introPage=intro_3.html2008;Accessed November 7
  29. Spratt KA. Reducing the risk of coronary heart disease via lipid reduction. J Am Osteopath Assoc. 2004;104(Suppl 7):9–13
  30. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141:1527–1534
  31. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125:61–67
  32. Ogden CL, Carroll MD, McDowell MA, Flegal KM. Obesity Among Adults in the United States—No Change Since 2003–2004. Hyattsville, MD: National Center for Health Statistics; 2007;NCHS data brief no 1
  33. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19:225–230
  34. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52:402–411
  35. Warrington KJ, Kent PD, Frye RL, et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther. 2005;7:R984–R991
  36. Malerba M, Gisondi P, Radaeli A, et al. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol. 2006;155:1165–1169
  37. McEwan P, Williams JE, Griffiths JD, et al. Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med. 2004;21:318–323
  38. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care. 2007;30:1292–1293
  39. Rosamond W, Flegal K, Furie K, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146
  40. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–79
  41. Lloyd-Jones D, Adams R, Carnethon M, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–e181
  42. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736–743
  43. Centers for Disease Control and Prevention (CDC). Prevalence of disabilities and associated health conditions among adults--United States, 1999. MMWR Morb Mortal Wkly Rep. 2001;50:120–125
  44. Centers for Disease Control and Prevention (CDC). Outpatient rehabilitation among stroke survivors—21 States and the District of Columbia, 2005. MMWR Morb Mortal Wkly Rep. 2007;56:504–507
  45. Feldman SR, Ravis S, Moran WP, Fleischer AB. Patients seen in a dermatology clinic have unmet preventive health care needs. J Am Acad Dermatol. 2001;44:706–709
  46. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58:1031–1042
  47. Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52:262–267

 Funding: Abbott Laboratories sponsored the clinical trials (M02-528, CHAMPION, REVEAL) and supported this retrospective analysis.

 Conflict of Interest: Consultancies: A.B. Kimball (Abbott Laboratories, Amgen, Biogen, Centocor, Genentech); Employment: Y. Bao (Abbott Laboratories), S. Gupta (Abbott Laboratories), P. Mulani (Abbott Laboratories), A. Guerin (Analysis Group, under contract with Abbott Laboratories), D. Latremouille-Viau (Analysis Group, under contract with Abbott Laboratories), A. Yu (Analysis Group, under contract with Abbott Laboratories).

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(09)01013-4

doi: 10.1016/j.amjmed.2009.08.022

The American Journal of Medicine
Volume 123, Issue 4 , Pages 350-357 , April 2010

Article Tools